Chapter Announces Summer Promo Membership Boost, Raffle Winners

Posted by ISPE Boston
On July 27, 2020

We would like to welcome all new and returning Boston Area Chapter ISPE members to the 2020-2021 program year! A special thank you and congratulations to our Summer Membership Promo raffle winners: Jessica Parenteau from Regeneron, Juergen Hahn from Levitronix and Yolanda McLean from Alnylam. ISPE recognizes the vital role our members play in […]

Pandion Therapeutics in $135M IPO

Posted by ISPE Boston
On July 24, 2020

Watertown-based, clinical-stage biotech Pandion Therapeutics has announced the initial public offering of 7,500,000 shares of its common stock at a public offering price of $18.00 per share, for gross proceeds of $135 million. The common stock is expected to begin trading on the Nasdaq Global Market on July 17, 2020 under the symbol “PAND.” The offering is expected to close on July […]

Glympse Bio Secures $46.7 Million Series B Financing

Posted by ISPE Boston
On July 23, 2020

Cambridge-based Glympse Bio has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases. NASH is a disease that impacts 16 million people in the U.S. and 100 million worldwide. The […]

Adagio Therapeutics Launches with $50M Series A Financing

Posted by ISPE Boston
On July 23, 2020

Waltham-based Adagio Therapeutics has launched with the closing of a $50 million Series A financing to advance its portfolio of coronavirus antibodies as both therapeutics and prophylactics against SARS-CoV-2 as well as future coronavirus outbreaks. Adagio’s antibody candidates have been uniquely engineered and optimized to provide broad protection against SARS-CoV-2, SARSCoV-1, and additional circulating bat […]

Relay Therapeutics in $400M IPO

Posted by ISPE Boston
On July 23, 2020

Cambridge-based Relay Therapeutics has announced an initial public offering of 20,000,000 shares of its common stock at a price to the public of $20.00 per share. The gross proceeds of the offering are expected to be $400 million. In addition, the underwriters have a 30-day option to purchase up to 3,000,000 additional shares of common […]

Congratulate this Year’s Chapter Awardees

Posted by ISPE Boston
On July 23, 2020

The Hank Moes Award: Richard Pierro, President and CEO of Superior Controls, and Past ISPE Boston Area Chapter President has been selected to receive the Hank Moes Award. Rick has a longstanding, consistent and extraordinary legacy of support of ISPE, and specifically the Boston Area Chapter. The Hank Moes award is not an annual award, […]

ISPE Releases Good Practice Guide: Critical Utilities GMP Compliance

Posted by ISPE Boston
On July 23, 2020

ISPE has announced the release of its latest guide, “ISPE Good Practice Guide: Critical Utilities GMP Compliance – How to Be Compliant and Ready to Prove It.” The Guide was cultivated by leading experts to help pharmaceutical organizations achieve and maintain their critical utility systems in a state of control, and then be able to […]

Keeping Up with COVID

Posted by ISPE Boston
On July 16, 2020

New information on the industry response to the pandemic is arriving at a fast and furious pace. The following links are provided to help you keep up to date: Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine; Phase 3 to Begin in Late July https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-enrollment-phase-2-study-its-mrna-vaccine Moderna and ROVI Announce Collaboration […]

Blueprint Medicines in $775M Collaboration with Genentech/Roche

Posted by ISPE Boston
On July 16, 2020

Blueprint Medicines, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, has entered into a global collaboration with Roche and Genentech, a member of the Roche Group, to develop and commercialize pralsetinib, an investigational precision therapy for the treatment of people with cancer driven by oncogenic RET alterations, including non-small […]

Kymera Inks $150M Deal with Sanofi for Immune-Inflammatory Diseases

Posted by ISPE Boston
On July 16, 2020

Kymera Therapeutics has entered into a strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as […]

Page 63 of 118«‹61 626364 65 ›»